VRDN - Viridian Therapeutics, Inc.\DE

QQQ $ 459.86 $ 0.43 (0.09 %)

DIA $ 407.95 $ -1.96 (-0.48 %)

SPY $ 548.56 $ -1.34 (-0.24 %)

TLT $ 99.56 $ 0.56 (0.57 %)

GLD $ 232.35 $ 1.92 (0.83 %)

Previous Close

$ 13.47

Open

$ 14.83

Bid

$ 13.62 x 100

Ask

$ 13.66 x 200

Day's Range

$ 13.64 - $ 14.87

52 Week Range

$ 10.93 - $ 24.18

Volume

1,633,711

Average Volume

Market Cap

860.6M

Beta (5Y Monthly)

$ 0.21

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-08-2024	06-30-2024	10-Q
2	05-08-2024	03-31-2024	10-Q
3	02-27-2024	12-31-2023	10-K
4	11-13-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-10-2023	03-31-2023	10-Q
7	03-09-2023	12-31-2022	10-K
8	11-14-2022	09-30-2022	10-Q
9	08-15-2022	06-30-2022	10-Q
10	05-13-2022	03-31-2022	10-Q
11	03-11-2022	12-31-2021	10-K
12	11-05-2021	09-30-2021	10-Q
13	08-12-2021	06-30-2021	10-Q
14	05-07-2021	03-31-2021	10-Q
15	03-26-2021	12-31-2020	10-K
16	11-12-2020	09-30-2020	10-Q
17	08-05-2020	06-30-2020	10-Q
18	05-08-2020	03-31-2020	10-Q
19	03-13-2020	12-31-2019	10-K
20	11-08-2019	09-30-2019	10-Q
21	08-08-2019	06-30-2019	10-Q
22	05-09-2019	03-31-2019	10-Q
23	03-14-2019	12-31-2018	10-K
24	11-07-2018	09-30-2018	10-Q
25	08-08-2018	06-30-2018	10-Q
26	05-09-2018	03-31-2018	10-Q
27	03-15-2018	12-31-2017	10-K
28	11-09-2017	09-30-2017	10-Q
29	08-11-2017	06-30-2017	10-Q
30	05-11-2017	03-31-2017	10-Q
31	03-24-2017	12-31-2016	10-K
32	10-26-2016	09-30-2016	10-Q
33	08-15-2016	06-30-2016	10-Q
34	05-16-2016	03-31-2016	10-Q
35	03-21-2016	12-31-2015	10-K
36	11-13-2015	09-30-2015	10-Q
37	08-14-2015	06-30-2015	10-Q
38	05-15-2015	03-31-2015	10-Q
39	03-27-2015	12-31-2014	10-K
40	11-14-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Needham Reiterates Buy on Viridian Therape...
08/30/2024 15:25:25

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $30 price target.

RBC Capital Reiterates Outperform on Virid...
08/28/2024 12:53:24

RBC Capital analyst Gregory Renza reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and maintains $35 price t...

Decoding 6 Analyst Evaluations For Viridia...
08/15/2024 12:01:38

HC Wainwright & Co. Reiterates Buy on Viri...
08/15/2024 10:23:47

HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $27 pri...

Oppenheimer Reiterates Outperform on Virid...
08/12/2024 13:48:18

Oppenheimer analyst Leland Gershell reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price ta...

Viridian Therapeutics Q2 2024 Adj EPS $(1....
08/08/2024 12:29:48

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate ...

top-3-health-care-stocks-you-may-want-to-dump-this-quarter

Top 3 Health Care Stocks You May Want To D...
07/30/2024 14:13:47

Wedbush Reiterates Outperform on Viridian ...
07/29/2024 12:57:38

Wedbush analyst Laura Chico reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and maintains $42 price target.

Viridian Therapeutics Completes Enrollment...
07/25/2024 12:05:20

- THRIVE-2 exceeded its enrollment target due to patient demand; 188 patients enrolled with approximately 40% from US sites -- ...

Expert Ratings For Viridian Therapeutics
07/16/2024 13:00:54

HC Wainwright & Co. Reiterates Buy on Viri...
07/16/2024 12:35:58

HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $27 pri...

Wolfe Research Initiates Coverage On Virid...
06/11/2024 18:16:24

Wolfe Research analyst Andy Chen initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Outperform rating.

Needham Reiterates Buy on Viridian Therape...
06/11/2024 17:23:54

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $30 price target.

12-health-care-stocks-moving-in-tuesdays-pre-market-session

12 Health Care Stocks Moving In Tuesday's ...
06/11/2024 12:06:21

Viridian Therapeutics Gives Details About ...
06/11/2024 10:04:18

7 Analysts Assess Viridian Therapeutics: W...
06/06/2024 15:00:53

Goldman Sachs Initiates Coverage On Viridi...
06/06/2024 13:05:43

Goldman Sachs analyst Richard Law initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Buy rating and announces ...

HC Wainwright & Co. Maintains Buy on Virid...
05/09/2024 19:03:54

HC Wainwright & Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price t...

Oppenheimer Maintains Outperform on Viridi...
05/09/2024 16:48:49

Oppenheimer analyst Leland Gershell maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price tar...

Ladenburg Thalmann Downgrades Viridian The...
05/09/2024 16:14:36

Ladenburg Thalmann analyst Michael Higgins downgrades Viridian Therapeutics (NASDAQ:VRDN) from Buy to Neutral.